However, upon retrospective testing, MET overexpression was detected in all prior biopsies, including in the treatment-naïve lung tumor at initial diagnosis and in the crizotinib- and lorlatinib-resistant tumor specimens (Fig. 2A; H-scores 300 and 300, respectively). The gene discussed is MET; the disease is neoplasm.